Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Farnesyl transferase inhibitors: current developments and future perspectives.

F A Eskens1, G Stoter, J Verweij

  • 1Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek), Rotterdam, The Netherlands. eskens@oncd.azr.nl

Cancer Treatment Reviews
|September 28, 2000
PubMed
Summary

Ras oncogene inhibition is a promising anticancer strategy. Farnesyl transferase inhibitors show potential, with early clinical studies defining new endpoints for treatment assessment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma activity of prolyl endopeptidase in relation to psychopathology during immunotherapy with IFN-alpha in patients with renal cell carcinoma.

Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research·2008
Same author

Serum proteomic patterns for ovarian cancer monitoring.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2007
Same author

Influence of pegylated interferon-alpha therapy on plasma levels of citrulline and arginine in melanoma patients.

Amino acids·2006
Same author

Parallel detection of transduced T lymphocytes after immunogene therapy of renal cell cancer by flow cytometry and real-time polymerase chain reaction: implications for loss of transgene expression.

Human gene therapy·2006
Same author

What is the role of dose-dense therapy?

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2005
Same author

Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytes.

Journal of biological regulators and homeostatic agents·2004

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Ras oncogenes are critical drivers of human carcinogenesis.
  • Ras oncoprotein activity, regulated by farnesyl transferase, is essential for tumor development.
  • Targeting farnesyl transferase is a key strategy in anticancer drug development.

Purpose of the Study:

  • To review the role of Ras oncogenes in cancer.
  • To discuss the development and therapeutic potential of farnesyl transferase inhibitors.
  • To highlight the need for new endpoints in clinical trials for these agents.

Main Methods:

  • Review of preclinical and clinical data on farnesyl transferase inhibitors.
  • Analysis of the mechanism of Ras-dependent carcinogenesis.

Related Experiment Videos

  • Evaluation of emerging clinical trial designs and endpoints.

    • Main Results:

    • Farnesyl transferase inhibitors demonstrate significant in vitro and in vivo antitumor activity.
    • Early clinical studies with these inhibitors are underway.
    • New endpoints are required to accurately assess clinical value.

    Conclusions:

    • Farnesyl transferase inhibitors represent a promising therapeutic avenue for Ras-driven cancers.
    • Further clinical investigation is necessary to establish their efficacy and optimal use.
    • Defining appropriate endpoints is crucial for successful clinical development.